239 Randomized trial of surgery versus radiotherapy in patients with stage IIIA non-small cell lung cancer after a response to induction-chemotherapy. Intergroup study 08941

Splinter, Ted A.W.; Kirkpatrick, A.; Darwish, S.; Meerbeeck, Jan Van

doi:10.1016/s0169-5002(97)89621-3

Cited by 11 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, patients without malignant LNs in the mediastinum are usually treated with straightforward surgical resection. Patients with diseased mediastinal LNs are candidates for induction chemotherapy, followed by surgery and/or radiotherapy [46][47][48][49][50]. It is therefore of considerable clinical interest to evaluate these mediastinal LNs as accurately as possible.…”

Section: Locoregional Lymph Node Stagingmentioning

confidence: 99%

“…Effective systemic therapy (induction chemotherapy (IC)), followed by resection with mediastinal dissection, is probably a better treatment option for these patients [46][47][48][49][50]112]. In these treatment regimes, it is well known that clearance of viable tumour cells in the mediastinum (downstaging) and pathological response in the primary tumour, are very important for prognosis [113][114][115][116][117][118].…”

Section: Assessment Of Response After Induction Chemotherapymentioning

confidence: 99%

See 1 more Smart Citation

Imaging in lung cancer: positron emission tomography scan

Vansteenkiste¹

2002

Eur Respir J

View full text Add to dashboard Cite

In the past 5 yrs, positron emission tomography (PET), usually used with 18 F-fluoro-2-deoxy-glucose (FDG), has become an important imaging modality in lung cancer patients.Currently, the use of FDG-PET in respiratory oncology is mainly for diagnosis and staging. Standard indications are the evaluation of an indeterminate solitary pulmonary nodule or mass, where FDG-PET has proven to be significantly more accurate than computed tomography (CT) in the distinction between benign and malignant lesions. Several studies have also convincingly demonstrated that locoregional lymph node staging by FDG-PET (in correlation with CT images) is significantly superior to CT, with a negative predictive value equal or even superior to mediastinoscopy. FDG-PET also improves extrathoracic staging, through the detection of lesions missed at conventional imaging or characterization of lesions that remain equivocal on conventional imaging. Many European countries now have or plan reimbursement in these indications. Large-scale randomized studies should now focus on the impact this accurate tumour imaging technique has on treatment outcome and cost-efficacy.Ongoing studies in specialized centres focus on the use of FDG-PET in more advanced clinical applications, such as planning radiotherapy, response evaluation after radiotherapy or (induction) chemotherapy, follow-up and early detection of recurrence, and prognostic information in this in vivo measurement of tumour glucose metabolism.After a short note on the technique used and a summary of the current common indications of diagnosis and staging, this paper will deal mainly with two of the more advanced clinical applications of FDG-PET in locally advanced nonsmall cell lung cancer: radiation treatment planning and assessment of induction chemotherapy.Finally, it should be mentioned that a whole new field of applications of positron emission tomography in molecular biology, using new radiopharmaceutical probes, is under extensive investigation. These techniques are promising for future use in very early response monitoring during chemo-or radiotherapy, in evaluation of novel molecular-targeted lung cancer therapies, or even gene therapy.

show abstract

Section: Locoregional Lymph Node Stagingmentioning

confidence: 99%

Section: Assessment Of Response After Induction Chemotherapymentioning

confidence: 99%

Imaging in lung cancer: positron emission tomography scan

Vansteenkiste¹

2002

Eur Respir J

View full text Add to dashboard Cite

show abstract

“…This trial will meet its accrual goals if the current pace is maintained. The second trial ongoing within the European Intergroup (Table 2) asks whether surgical resection or RT is the optimal local control after three cycles of induction chemotherapy with any cisplatin-containing regimen [50]. Safety data so far are favorable, and this trial will also complete its accrual.…”

Section: Phase III Trials In Advanced Stage Iiia(n2) Diseasementioning

confidence: 99%

Induction chemotherapy or chemoradiotherapy before surgery for non-small-cell lung cancer

Albain

2000

Curr Oncol Rep

View full text Add to dashboard Cite

Two controversies regarding the role of induction therapy before surgery in non-small-cell lung cancer are considered through a review of the literature and ongoing trials worldwide. The first debate asks whether surgery is indicated after induction chemotherapy or chemoradiotherapy for patients with advanced stage III disease. The second debate addresses disease presentations with early stage disease or radiographically negative but microscopically positive N2 involvement. The question raised for this group of patients is whether induction chemotherapy with or without radiotherapy should be routinely prescribed before the standard therapy of definitive surgery. For both controversies, data are provocative and in some subsets argue in favor of the more aggressive approach. However, changes in standard-of-care recommendations are premature. Thus, ongoing worldwide trials maintain control arms of chemoradiotherapy alone and of surgery alone in the advanced and early disease subsets, respectively.

show abstract

Induction Chemotherapy with or without Radiotherapy Followed by Surgery in Non-Small Cell Lung Cancer

Albain

1999

Progress and Perspective in the Treatment of Lung Cancer

View full text Add to dashboard Cite

239 Randomized trial of surgery versus radiotherapy in patients with stage IIIA non-small cell lung cancer after a response to induction-chemotherapy. Intergroup study 08941

Cited by 11 publications

References 0 publications

Imaging in lung cancer: positron emission tomography scan

Imaging in lung cancer: positron emission tomography scan

Induction chemotherapy or chemoradiotherapy before surgery for non-small-cell lung cancer

Induction Chemotherapy with or without Radiotherapy Followed by Surgery in Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About